CN116056711B - 吡啶-3-甲酸2-[4-[(2,3,4-三甲氧基苯基)甲基]哌嗪-1-基]乙酯的晶体形式和合成方法 - Google Patents

吡啶-3-甲酸2-[4-[(2,3,4-三甲氧基苯基)甲基]哌嗪-1-基]乙酯的晶体形式和合成方法

Info

Publication number
CN116056711B
CN116056711B CN202180056396.XA CN202180056396A CN116056711B CN 116056711 B CN116056711 B CN 116056711B CN 202180056396 A CN202180056396 A CN 202180056396A CN 116056711 B CN116056711 B CN 116056711B
Authority
CN
China
Prior art keywords
compound
composition
disease
application according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180056396.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN116056711A (zh
Inventor
N·巴克利
D·贝尔蒙特
S·白求恩
K·迪亚兹
B·豪瑟
M·G·金
K·卡纳安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ambria Pharmaceutical
Original Assignee
Ambria Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambria Pharmaceutical filed Critical Ambria Pharmaceutical
Publication of CN116056711A publication Critical patent/CN116056711A/zh
Application granted granted Critical
Publication of CN116056711B publication Critical patent/CN116056711B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN202180056396.XA 2020-06-30 2021-06-28 吡啶-3-甲酸2-[4-[(2,3,4-三甲氧基苯基)甲基]哌嗪-1-基]乙酯的晶体形式和合成方法 Active CN116056711B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063046123P 2020-06-30 2020-06-30
US202063046120P 2020-06-30 2020-06-30
US63/046,120 2020-06-30
US63/046,123 2020-06-30
PCT/US2021/039305 WO2022005928A1 (en) 2020-06-30 2021-06-28 Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin -1-yl]ethyl pyridine-3-carboxylate and methods of synthesis

Publications (2)

Publication Number Publication Date
CN116056711A CN116056711A (zh) 2023-05-02
CN116056711B true CN116056711B (zh) 2026-03-31

Family

ID=79314883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056396.XA Active CN116056711B (zh) 2020-06-30 2021-06-28 吡啶-3-甲酸2-[4-[(2,3,4-三甲氧基苯基)甲基]哌嗪-1-基]乙酯的晶体形式和合成方法

Country Status (8)

Country Link
EP (1) EP4171233A4 (https=)
JP (2) JP7792920B2 (https=)
KR (1) KR20230031320A (https=)
CN (1) CN116056711B (https=)
AU (1) AU2021299266A1 (https=)
CA (1) CA3188286A1 (https=)
IL (1) IL299547A (https=)
WO (1) WO2022005928A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235297A1 (en) * 2022-06-03 2023-12-07 Imbria Pharmaceuticals, Inc. Compounds and methods for increasing efficiency of cardiac metabolism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093662A (zh) * 2017-06-20 2020-05-01 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169279B2 (en) * 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102850296B (zh) * 2012-09-29 2015-01-07 瑞阳制药有限公司 曲美他嗪的制备方法
EP3976103A4 (en) * 2019-05-31 2023-06-28 Imbria Pharmaceuticals, Inc. Methods of altering cardiac remodeling using compounds that promote glucose oxidation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093662A (zh) * 2017-06-20 2020-05-01 安布里亚制药公司 用于提高心脏代谢效率的组合物和方法
WO2020243120A1 (en) * 2019-05-31 2020-12-03 Imbria Pharmaceuticals, Inc. Methods of treating fibrosis using compounds that promote glucose oxidation

Also Published As

Publication number Publication date
JP2026027462A (ja) 2026-02-18
JP2023532330A (ja) 2023-07-27
WO2022005928A1 (en) 2022-01-06
AU2021299266A1 (en) 2023-02-02
JP7792920B2 (ja) 2025-12-26
IL299547A (en) 2023-02-01
EP4171233A1 (en) 2023-05-03
CN116056711A (zh) 2023-05-02
KR20230031320A (ko) 2023-03-07
CA3188286A1 (en) 2022-01-06
EP4171233A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
JP7174132B2 (ja) オメカムチブメカルビルの塩及び塩を調製するプロセス
KR101190953B1 (ko) 메트포르민 타우린염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
KR101211227B1 (ko) 메트포르민 아스코르브산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
US20250074878A1 (en) Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
KR20110021692A (ko) 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학 조성물 및 그를 포함하는 복합제제
CN103833626A (zh) 西达本胺的晶型及其制备方法与应用
CN110218184A (zh) 诺德司他共晶及其制备方法
WO2022017478A1 (zh) 一种环己烷甲酰胺的新晶型及其制备方法
JP2026027462A (ja) ピリジン－３－カルボン酸２－［４－［（２，３，４－トリメトキシフェニル）メチル］ピペラジン－１－イル］エチルの結晶形態および合成方法
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
ES2814499T3 (es) Formas en estado sólido de sales de Nilotinib
CN118420593A (zh) 奥希替尼-2,6-二羟基苯甲酸晶型及其制备方法
CN115385871A (zh) 舒欣啶盐
WO2019065792A1 (ja) 結晶
CN105399725A (zh) 曲格列汀化合物其盐、晶体、药物组合物和用途
CN111825606A (zh) 一种伐度司他晶型及其制备方法
RU2779198C2 (ru) Кристаллическое вещество производного гетероциклиденацетамида
WO2026040323A1 (zh) 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用
WO2023236927A1 (zh) 4-羰基氨基异吲哚啉-1,3-二酮类化合物及其制备方法、药物组合及用途
CN116887818A (zh) 口服固体剂量制剂
CN121085931A (zh) 一种巴瑞克替尼与糖精共晶及其制备方法
CN121085932A (zh) 一种巴瑞克替尼与4-羟基苯甲酸共晶及其制备方法
CN107216339A (zh) 一种dppiv抑制剂马来酸盐的多晶型及其制备方法
CN121085929A (zh) 一种巴瑞克替尼与酸结晶形式及其制备方法
CN116354956A (zh) 维利西呱晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant